期刊文献+

低功率聚焦超声对胰腺癌化疗增敏作用的临床研究 被引量:6

Clinical research of the low-power HIFU on chemo-sensitivity enhancement effect in patients with advanced pancreatic cancer
下载PDF
导出
摘要 目的:观察并评价低功率高强度聚焦超声(HIFU)对胰腺癌患者化疗的增敏作用。方法:选择胰腺癌患者30例,分成两组,试验组(GP方案化疗+低功率HIFU)与对照组(单纯GP方案化疗)各15例。观察并比较两组间治疗前后的临床症状、影像学(B超和/或CT)、实验室检查(肿瘤标志物CA199等)以及多药耐药相关基因表达(包括MDR1 mRNA、MRP mRNA、p53等)等变化情况。结果:试验组临床症状较对照组明显减轻(P<0.05),影像学可评价病灶:试验组CR 0例,PR 0例,SD 11例,PD 4例,DCR为73.3%;对照组CR 0例,PR 0例,SD 7例,PD 8例,DCR为46.7%,两组比较差异有显著性(P<0.05)。与治疗前相比,试验组治疗后MDR1 mRNA、MRP mRNA及p53表达水平显著降低(3.65±0.54与1.98±0.61,3.19±0.48与1.38±0.32,1.75±0.45与0.96±0.48;P<0.01),而对照组则无明显变化(3.87±0.68与4.09±0.63,3.18±0.53与3.27±0.45,1.81±0.51与1.99±0.56;P>0.05)。结论:低功率HIFU对胰腺癌化疗有一定增敏作用,有可能进一步提高疗效,改善患者的生活质量。 Objective:To observe and evaluate the low-power HIFU on chemo-sensitivity enhancement effect in patients with advanced pancreatic cancer.Methods:Thirty cases with advanced pancreatic cancer were divided into two groups,15 in the trial group(the low-power HIFU + GP regimen) and 15 in the control group(GP regimen only).GP regimen was given every 3 weeks for two cycles,and the low-power HIFU was 300-400W.All patients were assessable for the clinical symptom,imaging findings(B ultrasound or CT),the peripheral blood CA199 and the expressions of multi-drug resistance-genes conaining MDR1 mRNA,MRP mRNA and p53 in the peripheral blood before and after chemotherapy.Results:The clinical symptoms of trial group was significantly than that of the control group after treatment(P 0.05).The disease control rate(DCR) was 73.3% in the trial group and 46.7% in the control group,there were statistically significant differences between two groups(P 0.05).The expression levels of MDR1 mRNA,MRP mRNA and p53 in the peripheral blood after treatment decreased significantly as compared with that before treatment in the trial group(3.65 ± 0.54 vs 1.98 ± 0.61,3.19 ± 0.48 vs 1.38 ± 0.32,1.75 ± 0.45 vs 0.96 ± 0.48;P 0.01),but no significant differences in the control group(3.87 ±0.68 vs 4.09 ±0.63,3.18 ±0.53 vs 3.27 ± 0.45,1.81 ± 0.51 vs 1.99 ± 0.56;P 0.05).The most frequent grade I/II treatment-related adverse events included diarrhea,nausea/vomiting and neutropenia.Conclusion:There is a certain sensitizing effect of the low power HIFU combined with chemotherapy in patients with advanced pancreatic cancer.
出处 《现代肿瘤医学》 CAS 2013年第8期1805-1808,共4页 Journal of Modern Oncology
基金 广东省科学技术厅面上项目资助(编号:2011B031800210)
关键词 高能聚焦超声 胰腺癌 化疗增敏 high intensive focused ultrasound pancreatic cancer chemo-sensitivity
  • 相关文献

参考文献13

二级参考文献66

共引文献105

同被引文献50

  • 1朱海文,陈龙云,侍红泰,裴冬,毛义翔,陈斌.调强放疗联合高强度聚焦超声热疗治疗局部晚期胰腺癌的临床疗效[J].医学信息(医学与计算机应用),2014,0(33):99-99. 被引量:2
  • 2熊六林,于晋生,费兴波,玉秋红,兰江,罗仁胜,黄晓波.建立猪胰腺高强度聚焦超声通道的探讨[J].中国超声医学杂志,2006,22(10):736-738. 被引量:4
  • 3Jian-Jun Li,Guo-Liang Xu,Mo-Fa Gu,Guang-Yu Luo,Zhang Rong,Pei-Hong Wu,Jian-Chuan Xia.Complications of high intensity focused ultrasound in patients with recurrent and metastatic abdominal tumors[J].World Journal of Gastroenterology,2007,13(19):2747-2751. 被引量:14
  • 4Jemal A,Siegel R,Ward E,et al.Cancer statistics,2007[J].CA Cancer J Clin,2007,57(1):43-66. 被引量:1
  • 5Burris HA 3rd,Moore MJ,Andersen J,et al.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:A randomized trial[J].J Clin Oncol,1997,15(6):2403-2413. 被引量:1
  • 6Sung HY,Jung SE,Cho SH,et al.Long-term outcome of high-intensity focused ultrasound in advanced pancreatic cancer[J].Pancreas,2011,40(7):1080-1086. 被引量:1
  • 7Sofuni A,Moriyasu F,Sano T,et al.The current potential of high-intensity focused ultrasound for pancreatic carcinoma[J].J Hepatobiliary Pancreat Sci,2011,18(3):295-303. 被引量:1
  • 8Louvet C,Labianca R,Hammel P,et al.Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer:Results of a GERCOR and GISCAD phase III trial[J].J Clin Oncol,2005,23(15):3509-3516. 被引量:1
  • 9Baize N,Abu S halaa A,Berthier F,et al.Gemcitabine combined with oxaliplatin is safe and effective in patients with previously untreated advanced pancreatic adenocarcinoma[J].Gastroenterol Clin Biol,2005,29(10):1006-1009. 被引量:1
  • 10Demols A,Peeters M,Polus M,et al.Gemcitabine and oxaliplatin(GEMOX)in gemcitabine refractory advanced pancreatic adenocarcinoma:A phase II study[J].Br J Cancer,2006,94(4):481-485. 被引量:1

引证文献6

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部